Capivasertib+Paclitaxel as First Line Treatment for Patients With Locally Advanced or Metastatic TNBC
Status:
Recruiting
Trial end date:
2023-03-24
Target enrollment:
Participant gender:
Summary
Phase III Study of Capivasertib + Paclitaxel versus Placebo + Paclitaxel as First line
Treatment for Patients with Locally Advanced or Metastatic Triple-negative Breast Cancer
(TNBC)